Integra LifeSciences (IART) to Release Earnings on Tuesday

Key Points

• Integra LifeSciences will report Q1 2026 results before the open on May 5, 2026; analysts expect $0.42 EPS and $381.8M revenue, while the company guided Q1 EPS of $0.370–$0.450 and FY 2026 EPS of $2.30–$2.40.
• The stock shows mixed signals: Integra beat the prior quarter's EPS ($0.83 vs. $0.79) but had a negative net margin and year‑over‑year revenue decline, and analysts' consensus rating is "Reduce" with a $14.20 target price.

Integra LifeSciences (NASDAQ:IART - Get Free Report) is projected to announce its Q1 2026 results before the market opens on Tuesday, May 5th. Analysts expect Integra LifeSciences to post earnings of $0.42 per share and revenue of $381.81 million for the quarter. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. Parties may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 8:30 AM ET.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its earnings results on Thursday, February 26th. The life sciences company reported $0.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.04. Integra LifeSciences had a negative net margin of 31.58% and a positive return on equity of 14.76%. The firm had revenue of $434.93 million during the quarter, compared to analysts' expectations of $429.62 million. During the same quarter last year, the company posted $0.97 earnings per share. The firm's revenue was down 1.7% compared to the same quarter last year. On average, analysts expect Integra LifeSciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Integra LifeSciences Stock Up 1.1%

Shares of NASDAQ IART opened at $10.69 on Tuesday. The company's 50-day simple moving average is $10.18 and its 200-day simple moving average is $11.80. Integra LifeSciences has a 52-week low of $8.70 and a 52-week high of $17.54. The firm has a market cap of $833.18 million, a price-to-earnings ratio of -1.59 and a beta of 1.06. The company has a quick ratio of 1.46, a current ratio of 2.54 and a debt-to-equity ratio of 1.66.

Analysts Set New Price Targets

IART has been the topic of several research analyst reports. Truist Financial dropped their target price on shares of Integra LifeSciences from $13.00 to $12.00 and set a "hold" rating on the stock in a research report on Wednesday, April 15th. Citigroup lowered their price target on shares of Integra LifeSciences from $11.00 to $9.00 and set a "sell" rating on the stock in a research report on Wednesday, March 11th. Wall Street Zen lowered shares of Integra LifeSciences from a "buy" rating to a "hold" rating in a research report on Saturday, March 7th. Wells Fargo & Company upgraded shares of Integra LifeSciences to a "hold" rating in a research report on Wednesday, March 18th. Finally, Argus restated a "hold" rating on shares of Integra LifeSciences in a research report on Wednesday, April 15th. One investment analyst has rated the stock with a Buy rating, three have issued a Hold rating and three have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Reduce" and a consensus target price of $14.20.

Hedge Funds Weigh In On Integra LifeSciences

Several institutional investors and hedge funds have recently bought and sold shares of IART. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Integra LifeSciences by 5.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company's stock valued at $889,000 after purchasing an additional 1,975 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in shares of Integra LifeSciences in the 1st quarter worth approximately $277,000. Goldman Sachs Group Inc. lifted its holdings in shares of Integra LifeSciences by 2.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,660,511 shares of the life sciences company's stock worth $36,515,000 after acquiring an additional 35,790 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Integra LifeSciences by 23.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 244,335 shares of the life sciences company's stock worth $5,373,000 after acquiring an additional 45,693 shares during the last quarter. Finally, Marshall Wace LLP purchased a new stake in Integra LifeSciences during the 2nd quarter worth approximately $491,000. 84.78% of the stock is currently owned by institutional investors and hedge funds.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.